Trials / Completed
CompletedNCT05236907
The Efficacy of Oral Melatonin in Preventing Postoperative Delirium for Patients Undergoing Orthopedic Surgery Under General Anesthesia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- University of Baghdad · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Postoperative delirium is a complication that should not be underestimated. As it elaborates many complications that could be avoided when an accurate assessment of the risk factors and interventional measures are taken appropriately when needed.
Detailed description
Delirium is a variation in concentration capabilities that occurs acutely in association with a disturbed level of consciousness. Delirium is more common in orthopaedic surgery patients than in general surgery patients. As delirium ratios range from 44% to 55% in hip surgery patients, otherwise only 10%-14% of general surgery patients. Several studies were carried out and found that melatonin levels correlate with the development of delirium postoperatively. This study was conducted to determine the efficacy of administering melatonin preoperatively in patients undergoing orthopedic surgery to prevent postoperative delirium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melatonin | The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively. |
| OTHER | No intervention | No intervention was used. |
| DRUG | Midazolam | 7.5 mg of Midazolam orally. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2020-10-30
- Completion
- 2020-11-01
- First posted
- 2022-02-11
- Last updated
- 2022-02-11
Locations
2 sites across 1 country: Iraq
Source: ClinicalTrials.gov record NCT05236907. Inclusion in this directory is not an endorsement.